相关实验视频

Updated: May 11, 2026

The Influence of Liver Resection on Intrahepatic Tumor Growth

The Influence of Liver Resection on Intrahepatic Tumor Growth

Published on: April 9, 2016

化疗后残留或切除的消失性肝转移的评估:AROD研究

Kosuke Kobayashi¹, Atsushi Oba¹, Sho Kiritani¹

¹Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Annals of surgery

|August 29, 2025

概括

大约10%的消失的肝转移 (DLM) 含有残留疾病. 这突显了需要精确的成像和选择性切除策略来管理这些结肠直肠癌病变.

科学领域:

癌症学
放射学
病理学

背景情况:

消失性肝转移 (DLM) 是结直肠肝转移,在化疗后无法检测到.
尽管使用现代疗法越来越多地观察到DLM,但其临床意义和治疗仍然不清楚.

研究的目的:

预期评估DLM的残留疾病发生率.
评估与DLM相关的瘤结果.

主要方法:

一个癌症研究所的观察队列研究.
DLM定义为CT/MRI无法检测到的肝转移.
切除DLM的病理检查和未切除DLM的成像监测.

主要成果:

9. 3% 的 DLM 确实有残留疾病 (病理或临床).
对于未切除的DLM,在6个月后的复发率为2. 2%,在12个月后为7. 7%.
56. 5% 的患者出现复发,有些人需要重复切除.

结论:

大约有10%的DLM患有残留疾病.
结果支持基于手术内评估的选择性切除.
强调精确的成像和术后监测对DLM的重要性.

关键词:

化学疗法大肠直肠肝转移消失的肝转移肝切除术

更多相关视频

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis

Published on: March 3, 2023

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...